Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a

Retrieved on: 2021-09-07 06:00:00

Tags for this article:

Medical specialties

Clinical medicine

Medicine

Immunology

Monoclonal antibodies

Foralumab

Anti-CD3 monoclonal antibody

Crohn's disease

Immunotherapy

Autoimmune disease

Cytokine release syndrome

Interleukin-6 receptor

Tiziana Life Sciences PLC

Click the tags to see associated articles and topics

Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a. View article details on HISWAI: https://www.kulr8.com/news/money/tiziana-to-host-investor-call-to-discuss-exclusive-license-agreement-to-evaluate-foralumab-a/article_750097d2-b918-53e6-91b8-68eed9f3afcb.html

Excerpt

07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative ...

Article found on: www.kulr8.com

View Original Article